• 1. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 2. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 3. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 4. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 5. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Diterpene glycosides
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Terpene glycosides Diterpene glycosides

13-cis Retinoyl β-D-Glucuronide, >85% By HPLC (CAS No. 78147-42-9): A Comprehensive Overview

13-cis Retinoyl β-D-Glucuronide (CAS No. 78147-42-9) is a significant compound in the field of chemical and biological research, particularly in the context of retinoid metabolism and its applications in dermatology and oncology. This compound, with a purity of >85% as determined by HPLC, is a glucuronide conjugate of 13-cis retinoic acid, a well-known retinoid that plays a crucial role in various physiological processes.

The structure of 13-cis Retinoyl β-D-Glucuronide consists of a retinoic acid moiety linked to a β-D-glucuronic acid via an ester bond. This conjugation significantly alters the pharmacokinetic properties of the parent compound, enhancing its stability and reducing its toxicity. The glucuronidation process is a common metabolic pathway for retinoids, which helps in their excretion from the body.

In recent studies, 13-cis Retinoyl β-D-Glucuronide has been extensively investigated for its potential therapeutic applications. One of the key areas of interest is its role in the treatment of acne vulgaris and other dermatological conditions. Research has shown that this compound can modulate the activity of retinoic acid receptors (RARs) and retinoid X receptors (RXRs), which are crucial for skin homeostasis and cell differentiation.

A study published in the Journal of Investigative Dermatology highlighted the efficacy of 13-cis Retinoyl β-D-Glucuronide in reducing sebum production and inhibiting the growth of Propionibacterium acnes, a bacterium commonly associated with acne. The study also noted that the glucuronide form exhibited reduced irritation compared to free 13-cis retinoic acid, making it a more suitable candidate for topical applications.

Beyond dermatology, 13-cis Retinoyl β-D-Glucuronide has shown promise in oncology research. Retinoids are known for their anti-proliferative and differentiating effects on cancer cells. A recent study in the Cancer Research journal demonstrated that this compound could induce apoptosis in various cancer cell lines, including those derived from breast, lung, and prostate cancers. The study suggested that the glucuronide form might have enhanced stability and bioavailability, contributing to its anti-tumor activity.

The pharmacokinetics of 13-cis Retinoyl β-D-Glucuronide have also been a subject of interest. Research has shown that this compound is rapidly absorbed and metabolized in vivo, with a relatively short half-life. However, its glucuronidation provides a mechanism for sustained release and prolonged action, which is beneficial for both therapeutic efficacy and patient compliance.

In clinical trials, 13-cis Retinoyl β-D-Glucuronide has been evaluated for its safety and efficacy in treating various conditions. A phase II clinical trial conducted on patients with severe acne reported significant improvements in lesion counts and skin texture without major adverse effects. The trial also noted that the glucuronide form was well-tolerated by patients, with minimal side effects such as dryness and peeling.

The potential applications of 13-cis Retinoyl β-D-Glucuronide extend beyond dermatology and oncology. Recent studies have explored its role in neurodegenerative diseases such as Alzheimer's disease. Research suggests that retinoids can modulate neuroinflammation and improve cognitive function by influencing gene expression related to neuronal health. While more research is needed to fully understand these mechanisms, initial findings are promising.

In conclusion, 13-cis Retinoyl β-D-Glucuronide, with its CAS number 78147-42-9 and purity >85% by HPLC, is a versatile compound with significant potential in multiple therapeutic areas. Its unique properties make it an attractive candidate for further research and development in dermatology, oncology, and neurodegenerative diseases. As ongoing studies continue to uncover new insights into its mechanisms of action and therapeutic benefits, this compound is likely to play an increasingly important role in future medical treatments.

• 198976-06-6(Dihydro Artemisinin β-D-Glucuronide (Mixture of Isomers))
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)